Abstract: A fuel cell vehicle includes a first current amount calculating unit that calculates a first total amount of current output from a fuel cell during a period from a predetermined timing to the present time, a hydrogen amount calculating unit that calculates a hydrogen total amount output from a hydrogen tank during the period from the predetermined timing to the present time, a remaining amount acquisition unit that acquires a hydrogen remaining amount in the hydrogen tank, and a current amount prediction unit that predicts a current amount that can be supplied by the fuel cell based on the first total amount, the total amount, and the hydrogen remaining amount.

Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

Abstract: An ultrasound generation member according to an aspect of the present invention includes an ultrasound generation element configured to emit ultrasound in a direction of a target object in one specific container of a plurality of containers. An ultrasound emission device according to an aspect of the present invention includes the ultrasound generation member, and a drive power supply configured to apply voltage across the ultrasound generation element of the ultrasound generation member. An ultrasound emission device according to an aspect of the present invention includes the ultrasound generation member that includes, as the ultrasound generation element, a plurality of ultrasound generation elements, and a drive power supply configured to apply voltage across the plurality of ultrasound generation elements of the ultrasound generation member.

Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

Abstract: A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B12 to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B12.

Abstract: A method for discriminating between Parkinson's disease and multiple system atrophy, the method comprising the steps of: (1) preparing a solution containing ?-synuclein monomers having a tendency to produce rod-like aggregates and/or a solution containing ?-synuclein monomers having a tendency to produce twisted aggregates; (2) adding a biological sample from a subject to the solution(s) containing the ?-synuclein monomers prepared in step (1); (3) allowing the ?-synuclein monomers to aggregate in the solution(s) obtained in step (2); and (4) detecting ?-synuclein aggregates formed in step (3).

Abstract: The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of ?-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an ?-synudein gene, has activity for inhibiting expression of the ?-synudein gene, and is complementary to the ?-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.

Abstract: Provided is an immunogenic composition comprising an antigenic peptide capable of inducing production of a neutralizing antibody against S100A9 and a carrier protein. The immunogenic composition can be used as a highly safe antithrombotic vaccine having antithrombotic effect without a long-term bleeding risk and is useful for the prevention of a disease associated with thrombus formation in which platelet aggregation is involved, particularly for the prevention of recurrent ischemic stroke.

Abstract: A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B12 to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B12.

Abstract: The objective of the present invention is to provide nucleic acid therapeutics which exhibits more excellent effect and which shows a substantivity for a prolonged period to suppress an expression of ?-synuclein. The oligonucleotide or a pharmacologically acceptable salt thereof according to the present invention is characterized in comprising at least one 2?-O,4?-C-ethylene nucleoside, wherein the oligonucleotide can hybridize with ?-synuclein gene, has an activity to suppress an expression of the ?-synuclein gene, and is complementary to the ?-synuclein gene, 5? end of the oligonucleotide is a nucleotide complementary to the specific nucleotide, the oligonucleotide is complementary to at least a part of SEQ ID NO: 1, and the oligonucleotide has a length of 13 or more and 15 or less nucleotides.

Abstract: An ultrasound generation member according to an aspect of the present invention includes an ultrasound generation element configured to emit ultrasound in a direction of a target object in one specific container of a plurality of containers. An ultrasound emission device according to an aspect of the present invention includes the ultrasound generation member, and a drive power supply configured to apply voltage across the ultrasound generation element of the ultrasound generation member. An ultrasound emission device according to an aspect of the present invention includes the ultrasound generation member that includes, as the ultrasound generation element, a plurality of ultrasound generation elements, and a drive power supply configured to apply voltage across the plurality of ultrasound generation elements of the ultrasound generation member.

Abstract: Provided is an immunogenic composition comprising an antigenic peptide capable of inducing production of a neutralizing antibody against S100A9 and a carrier protein. The immunogenic composition can be used as a highly safe antithrombotic vaccine having antithrombotic effect without a long-term bleeding risk and is useful for the prevention of a disease associated with thrombus formation in which platelet aggregation is involved, particularly for the prevention of recurrent ischemic stroke.

Abstract: The present invention provides a therapeutic agent for myotonic dystrophy which inhibits aberrant splicing responsible for myotonic dystrophy, resulting in an increase in a normally spliced product and thus improvement in a symptom of myotonic dystrophy, and is highly safe for use in long-term administration. The therapeutic agent for myotonic dystrophy comprises, as an active ingredient, at least one compound selected from the group consisting of erythromycin, clarithromycin and azithromycin, a pharmaceutically acceptable salt or hydrate thereof, or a prodrug thereof.

Abstract: A thermoplastic elastomer composition obtained by dynamically crosslinking an ethylene/?-olefin/non-conjugated polymer copolymer (A), a polyolefin resin (B), a softener (C) in an amount of 1 to 200 parts by mass per 100 parts by mass of the total of the copolymer (A) and the resin (B), and a crosslinking agent (D) by the use of a batch mixer under the conditions satisfying the requirements (1) to (4).

Abstract: Provided is a thermoplastic elastomer composition with which it is possible to obtain a molded article having exceptional low-temperature impact resistance. A thermoplastic elastomer composition is produced that contains a crystalline olefin polymer (A) and an ethylene-?-olefin (C4-20)-unconjugated polyene copolymer (B) that satisfies requirements (1) and (2). (1) The B value represented by the equation: ([EX]+2[Y])/(2×[E]×([X]+[Y])) is 1.20 or higher. [E], [X] and [Y] respectively indicate the molar fraction of structural units derived from ethylene, the molar fraction of structural units derived from C4-20 ?-olefin and the molar fraction of structural units derived from unconjugated polyene, and [EX] indicates the diad chain fraction of structural units derived from ethylene-structural units derived from C4-20 ?-olefin. (2) The molar ratio of structural units derived from ethylene with respect to structural units derived from ?-olefin (C4-20) of copolymer (B) is 40/60-90/10.

Abstract: The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of ?-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an ?-synudein gene, has activity for inhibiting expression of the ?-synudein gene, and is complementary to the ?-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.

Abstract: The present invention provides a therapeutic agent for myotonic dystrophy which inhibits aberrant splicing responsible for myotonic dystrophy, resulting in an increase in a normally spliced product and thus improvement in a symptom of myotonic dystrophy, and is highly safe for use in long-term administration. The therapeutic agent for myotonic dystrophy comprises, as an active ingredient, at least one compound selected from the group consisting of erythromycin, clarithromycin and azithromycin, a pharmaceutically acceptable salt or hydrate thereof, or a prodrug thereof.

Abstract: Provided is a thermoplastic elastomer composition with which it is possible to obtain a molded article having exceptional low-temperature impact resistance. A thermoplastic elastomer composition is produced that contains a crystalline olefin polymer (A) and an ethylene-?-olefin (C4-20)—unconjugated polyene copolymer (B) that satisfies requirements (1) and (2). (1) The B value represented by the equation: ([EX]+2[Y])/(2×[E]×([X]+[Y])) is 1.20 or higher. [E], [X] and [Y] respectively indicate the molar fraction of structural units derived from ethylene, the molar fraction of structural units derived from C4-20 ?-olefin and the molar fraction of structural units derived from unconjugated polyene, and [EX] indicates the diad chain fraction of structural units derived from ethylene-structural units derived from C4-20 ?-olefin. (2) The molar ratio of structural units derived from ethylene with respect to structural units derived from ?-olefin (C4-20) of copolymer (B) is 40/60-90/10.

Abstract: A thermoplastic elastomer composition obtained by dynamically crosslinking an ethylene/?-olefin/non-conjugated polymer copolymer (A), a polyolefin resin (B), a softener (C) in an amount of 1 to 200 parts by mass per 100 parts by mass of the total of the copolymer (A) and the resin (B), and a crosslinking agent (D) by the use of a batch mixer under the conditions satisfying the requirements (1) to (4).